-
1
-
-
78650874372
-
Su11248 inhibits kit and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-478.
-
(2003)
Mol. Cancer Ther
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
-
2
-
-
9144274970
-
Su11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-766.
-
(2003)
Clin. Exp. Metastasis
, vol.20
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
-
3
-
-
0038204144
-
Su11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605.
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
O'Farrell, A.M.1
Abrams, T.J.2
Yuen, H.A.3
-
4
-
-
12444297983
-
The receptor tyrosine kinase inhibitor su11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
-
Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7:225-233.
-
(2004)
Angiogenesis
, vol.7
, pp. 225-233
-
-
Osusky, K.L.1
Hallahan, D.E.2
Fu, A.3
-
5
-
-
0041672482
-
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models
-
(Pubitemid 36917920) Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63:4009-16.
-
(2003)
Cancer Research
, vol.63
, Issue.14
, pp. 4009-4016
-
-
Schueneman, A.J.1
Himmelfarb, E.2
Geng, L.3
Tan, J.4
Donnelly, E.5
Mendel, D.6
McMahon, G.7
Hallahan, D.E.8
-
6
-
-
33644840580
-
Targeted therapy for metastatic renal cell carcinoma
-
DOI 10.1038/sj.bjc.6602978, PII 6602978
-
(Pubitemid 43361889) Patel P, Motzer R. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94:614-9.
-
(2006)
British Journal of Cancer
, vol.94
, Issue.5
, pp. 614-619
-
-
Patel, P.H.1
Chaganti, R.S.K.2
Motzer, R.J.3
-
7
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
DOI 10.1200/JCO.2005.02.2194
-
(Pubitemid 46630490) Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35.
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
Robert, C.4
Lozahic, S.5
Lassau, N.6
Bello, C.7
Deprimo, S.8
Brega, N.9
Massimini, G.10
Armand, J.-P.11
Scigalla, P.12
Raymond, E.13
-
8
-
-
38649129787
-
New developments in multitargeted therapy for patients with solid tumours
-
DOI 10.1016/j.ctrv.2007.09.003, PII S0305737207001375
-
(Pubitemid 351168610) Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2007; 34:37-48.
-
(2008)
Cancer Treatment Reviews
, vol.34
, Issue.1
, pp. 37-48
-
-
Le Tourneau, C.1
Faivre, S.2
Raymond, E.3
-
9
-
-
44449171930
-
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
-
Rosenbaum S, Wu S, Newman M, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16:557-566.
-
(2008)
Support Care Cancer
, vol.16
, pp. 557-566
-
-
Rosenbaum, S.1
Wu, S.2
Newman, M.3
-
10
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
DOI 10.1056/NEJMoa065044
-
(Pubitemid 46089672) Motzer R, Hutson TE, Tomczak P, et al. Sunitinib vs interferon alfa in metastatic renal cell cancer. N Eng J Med 2007; 356:115-24.
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
11
-
-
42449148017
-
Sunitinib as second-line treatment for advanced gastric cancer: Preliminary results from a phase II study
-
Abstract 4603
-
Bang Y, Kang Y, Kang W, et al. Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study. J Clin Oncol 2007; 25 (18 suppl) :223s (Abstract 4603).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
Bang, Y.1
Kang, Y.2
Kang, W.3
-
12
-
-
85031340399
-
-
Sutent sunitinib malate, prescribing information: New York, NY: Pfizer;. Available at, Accessed: December 17
-
Sutent (sunitinib malate) [prescribing information]: New York, NY: Pfizer; 2003. Available at: http://www.pfizer.com/pfizer/download/uspi-sutent. pdf. Accessed: December 17, 2008.
-
(2003)
-
-
-
13
-
-
34047195479
-
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma
-
Speca J, Yenser S, Creel P, et al. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer 2006; 5 (suppl 1) :S24-30.
-
(2006)
Clin Genitourin Cancer
, vol.5
, Issue.1
-
-
Speca, J.1
Yenser, S.2
Creel, P.3
-
14
-
-
0003575142
-
-
National Cancer Institute: Available at:, Accessed: January 6
-
National Cancer Institute: Common Toxicity Criteria V. Available at: https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome-to-ctcae.htm. Accessed: January 6, 2009.
-
(2009)
Common Toxicity Criteria V.
-
-
-
17
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
-
(2006)
Jama
, vol.295
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
-
18
-
-
33749505836
-
Efficacy and safety of sunitinb in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinb in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338.
-
(2006)
Lancet
, vol.368
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
-
19
-
-
34648873387
-
Sunitinib in metastatic renal cell carcinoma (mRCC) : Preliminary assessment in an expanded access trial with subpopulation analysis
-
Abstract 5010
-
Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) : preliminary assessment in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 25 (18 suppl) :237s (Abstract 5010).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
Gore, M.E.1
Porta, C.2
Oudard, S.3
-
20
-
-
36749082718
-
Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy
-
Abstract 10022
-
Reichardt P, Kang YK, Ruka W, et al. Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy. J Clin Oncol 2007; 25 (18 suppl) :550s (Abstract 10022).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
Reichardt, P.1
Kang, Y.K.2
Ruka, W.3
-
21
-
-
33750631676
-
Efficacy and safety of sunitinib malate (SU11248, sutent) in bevacizumab-refractory metastatic renal cell carcinoma
-
Abstract 4522
-
Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248, Sutent) in bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (18 suppl) :222s (Abstract 4522).
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.18
-
-
Rini, B.I.1
George, D.J.2
Michaelson, M.D.3
-
22
-
-
35548945277
-
Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: Updated results
-
Abstract 5040
-
Srinivas S, Roigas J, Gillessen U, et al. Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: updated results. J Clin Oncol 2007; 25 (18 suppl) :244s (Abstract 5040).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
Srinivas, S.1
Roigas, J.2
Gillessen, U.3
-
23
-
-
36749083833
-
Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST
-
Abstract 10015
-
George S, Blay JY, Casali PG, et al. Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST. J Clin Oncol 2007; 25 (18 suppl) :548s (Abstract 10015).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
George, S.1
Blay, J.Y.2
Casali, P.G.3
-
24
-
-
38349102230
-
Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
-
Chu D, Lacouture M, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncologica 2008; 47:176-186.
-
(2008)
Acta. Oncologica.
, vol.47
, pp. 176-186
-
-
Chu, D.1
Lacouture, M.2
Fillos, T.3
-
25
-
-
32444439875
-
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
-
DOI 10.1016/j.ejca.2005.11.014, PII S0959804905010701
-
(Pubitemid 43227936) Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006; 42:548-56.
-
(2006)
European Journal of Cancer
, vol.42
, Issue.4
, pp. 548-556
-
-
Strumberg, D.1
Awada, A.2
Hirte, H.3
Clark, J.W.4
Seeber, S.5
Piccart, P.6
Hofstra, E.7
Voliotis, D.8
Christensen, O.9
Brueckner, A.10
Schwartz, B.11
-
26
-
-
0033122792
-
Capecitabine: Nursing implications of a new oral chemotherapeutic agent
-
Mrozek-Orlowski M, Frye DK, Sandborn HM, et al. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999; 26:753-62.
-
(1999)
Oncol. Nurs. Forum.
, vol.26
, pp. 753-762
-
-
Mrozek-Orlowski, M.1
Frye, D.K.2
Sandborn, H.M.3
-
27
-
-
0028280287
-
Epithelial-stromal interactions in basal cell cancer: The PDGF system
-
(Pubitemid 24095495) Ponten F, Ren Z, Nister M, et al. Epithelial-stromal interactions in basal cell cancer: the PDGF system. J Invest Dermatology 1994; 102:304-9.
-
(1994)
Journal of Investigative Dermatology
, vol.102
, Issue.3
, pp. 304-309
-
-
Ponten, F.1
Ren, Z.2
Nister, M.3
Westermark, B.4
Ponten, J.5
-
28
-
-
0028116487
-
Expression of c-kit and kit ligand proteins in normal human tissues
-
(Pubitemid 24338014) Lammie A Drobnjak M, Gerald W, et al. Expression of C-Kit and Kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42:1417-25.
-
(1994)
Journal of Histochemistry and Cytochemistry
, vol.42
, Issue.11
, pp. 1417-1425
-
-
Lammie, A.1
Drobnjak, M.2
Gerald, W.3
Saad, A.4
Cote, R.5
Cordon-Cardo, C.6
-
30
-
-
33845313345
-
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
-
DOI 10.1016/j.ejca.2006.09.015, PII S0959804906008483
-
(Pubitemid 44869016) Eskens F, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42:3127-39.
-
(2006)
European Journal of Cancer
, vol.42
, Issue.18
, pp. 3127-3139
-
-
Eskens, F.A.L.M.1
Verweij, J.2
-
31
-
-
1442290142
-
Combined inhibition of VEGF and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms
-
Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18:338-340.
-
(2004)
Faseb. J.
, vol.18
, pp. 338-340
-
-
Erber, R.1
Thurnher, A.2
Katsen, A.D.3
-
32
-
-
39049121694
-
Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
-
Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
-
(2008)
Br. J. Dermatol.
, vol.158
, pp. 592-596
-
-
Yang, C.H.1
Lin, W.C.2
Chuang, C.K.3
-
34
-
-
0034731423
-
Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes
-
DOI 10.1074/jbc.M003716200
-
(Pubitemid 32054928) Schmidt M, Goebeler M, Posern G, et al. Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes. J Biol Chem 2000; 275:41011-7. (Pubitemid 32054928)
-
(2000)
Journal of Biological Chemistry
, vol.275
, Issue.52
, pp. 41011-41017
-
-
Schmidt, M.1
Goebeler, M.2
Posern, G.3
Feller, S.M.4
Seitz, C.S.5
Brocker, E.-B.6
Rapp, U.R.7
Ludwig, S.8
-
35
-
-
41949099104
-
Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study
-
Abstract 9007
-
Lee S, Lee S, Chun Y, et al. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: results of a randomized double-blind placebo-controlled study. J Clin Oncol 2007; 25 (18 suppl) :494s (Abstract 9007).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
Lee, S.1
Lee, S.2
Chun, Y.3
-
36
-
-
35548991359
-
The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)
-
Abstract 5036
-
Stadler WM, Figlin RA, Ernstoff MS, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007; 25 (18 suppl) :243s (Abstract 5036).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
-
-
Stadler, W.M.1
Figlin, R.A.2
Ernstoff, M.S.3
-
37
-
-
36749078435
-
Phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma
-
Abstract 5080
-
Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. J Clin Oncol 2007; 15 (18 suppl) :254s (Abstract 5080).
-
(2007)
J. Clin. Oncol.
, vol.15
, Issue.18
-
-
Gallagher, D.J.1
Milowsky, M.I.2
Gerst, S.R.3
-
38
-
-
34547681379
-
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
-
DOI 10.1200/JCO.2006.07.2066
-
(Pubitemid 47218051) Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25:3045-54.
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.21
, pp. 3045-3054
-
-
Drevs, J.1
Siegert, P.2
Medinger, M.3
Mross, K.4
Strecker, R.5
Zirrgiebel, U.6
Harder, J.7
Blum, H.8
Robertson, J.9
Jurgensmeier, J.M.10
Puchalski, T.A.11
Young, H.12
Saunders, O.13
Unger, C.14
|